GMP compliance – Page 12

Bracketing and Matrixing Misuse in Generic Drug Submissions

Mitigating Bracketing and Matrixing Misuse in Generic Drug Submissions In the pharmaceutical sector, the proper execution of stability studies is crucial for ensuring the efficacy and safety of drug products.…

Ongoing Stability Program Deficiencies Found During FDA Inspections

Addressing Ongoing Gaps in Stability Programs Identified During FDA Inspections Ongoing stability program deficiencies can significantly impact regulatory compliance, product quality, and ultimately, patient safety. Recently, FDA inspections have highlighted…

Why Packaging Configuration Differences Can Break Bracketing Logic

Addressing the Challenges of Differing Packaging Configurations in Bracketing Logic The complexities of pharmaceutical stability studies can often lead to significant issues when bracketing and matrixing strategies are incorrectly implemented.…

How to Investigate Late or Missed Ongoing Stability Time Points

Effective Investigation of Delayed or Missed Ongoing Stability Time Points In the highly regulated pharmaceutical industry, the integrity of stability studies is paramount. Delays or missed time points in ongoing…

Matrixing Stability Study Designs That Inspectors Frequently Challenge

Challenges in Matrixing Stability Study Designs and Solutions for Compliance In the realm of pharmaceutical manufacturing, the implementation of bracketing and matrixing in stability studies can frequently encounter challenges that…

Ongoing Stability Sample Pull Misses and CAPA Requirements

Addressing Gaps in Ongoing Stability Programs: A Step-by-Step Approach In the realm of pharmaceutical manufacturing, ongoing stability program gaps can have significant implications for product quality, regulatory compliance, and patient…

How Misuse of Bracketing Creates Shelf-Life Approval Delays

How Misapplication of Bracketing in Stability Studies Can Lead to Shelf-Life Approval Delays In the pharmaceutical industry, the misapplication of bracketing and matrixing strategies in stability studies can pose significant…

How to Manage Ongoing Stability for Bracketed and Matrixed Products

Managing Gaps in Ongoing Stability Programs for Bracketed and Matrixed Products Managing ongoing stability for bracketed and matrixed pharmaceutical products is a critical component of quality assurance and regulatory compliance.…

Bracketing vs Matrixing: When Each Reduced Design Is Appropriate

Understanding the Appropriate Use of Bracketing and Matrixing in Stability Studies The application of bracketing and matrixing strategies in stability studies is essential for effective shelf-life management and compliance with…

Ongoing Stability Program Gaps in Multi-Strength Product Families

Addressing Gaps in Ongoing Stability Programs for Multi-Strength Product Families In the highly regulated pharmaceutical environment, ongoing stability program gaps within multi-strength product families can lead to significant compliance issues…

Common Errors in Matrixing Stability Timepoints and Sample Pulls

Identifying and Addressing Common Issues with Bracketing and Matrixing in Stability Studies Pharmaceutical professionals often encounter challenges during stability studies, particularly when dealing with bracketing and matrixing methodologies. Misuse of…

How to Trend Ongoing Stability Data for APR and PQR Reviews

Effective Methods to Address Ongoing Stability Program Gaps In the realm of pharmaceutical manufacturing, ongoing stability programs are critical to ensuring product quality throughout its lifecycle. Stability data trending must…